Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Optimizing Antidepressant Treatment by ABCB1 Genotype-dependent Dose Adjustment
2011-003190-29Phase 4Active
- Sponsor
- HMNC Brain Health
- Start
- Aug 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4 trial of paroxetine, sertraline, citalopram, escitalopram, venlafaxine and 4 more in major depressive disorder (MDD), sponsored by HMNC Brain Health. Primary endpoint: Partial response in HAM-D. Started Aug 2011; status: active.
02
Drugs
paroxetinesertralinecitalopramescitalopramvenlafaxine
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on 2011-003190-29.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-003190-29.